Delcath Systems (NASDAQ:DCTH) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.
This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation.
View the webcast at https://viavid.webcasts.com/starthere.jsp?ei=1773540&tp_key=7840303563
Summary
Delcath Systems reported record third-quarter 2026 revenue of $35.1 million, a 71% increase from Q3 2025, driven by the HEPZATO KIT and the addition of new treatment centers.
The company now has 33 active treatment centers in the U.S., with plans to increase to at least 36 by year-end 2026, including partnerships with major health systems like AdventHealth.
The Phase 2 colorectal trial is progressing, with an interim analysis expected mid-2027, while enrollment in the breast cancer trial is slower than anticipated.
For Q3 2026, the company achieved a gross margin of 89% and net income of $7 million, with positive cash flow from operations.
Delcath Systems raised its 2026 full-year revenue guidance to $115-117 million, projecting significant growth in HEPZATO KIT volume and maintaining a strong gross margin.
Full Transcript
OPERATOR
Good morning, ladies and gentlemen. Welcome to the Delcath Systems third quarter 2026 earnings conference call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star-zero for the operator. This call is being recorded on November 9, 2026. I would now like to turn the conference over to Mr. David Hoffman, Delcath General Counsel.
Please go ahead.
David L Hoffman (General Counsel)
Thank you and welcome to Delcath Systems’ third quarter 2026 earnings call. With me on the call are Gerard Michel, Chief Executive Officer; Sandra Pennell, SVP Finance; Kevin Muir, Chief Commercial Officer; Vojo Vukovic, Chief Medical Officer; and Martha Rook, Chief Operating Officer. This statement is made pursuant to the safe harbor for forward-looking statements described in the Private Securities Litigation Reform Act of 1995. All statements made on this call, with the exception of historical facts, may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the company believes that expectations and assumptions reflected in these forward-looking statements are reasonable, it makes no assurance that such expectations will prove to have been correct.
Actual results may differ in a material manner from those expressed or implied in forward-looking statements due to various risks and uncertainties. For a discussion of such risks and uncertainties, please see the risk factors detailed in the company’s Annual Report on Form 10-K, quarterly reports on Form 10-Q, and other reports that the company files from time to time with the Securities and Exchange Commission. Any forward-looking statements included in this call are made only as of the date of this call.
We do not undertake any obligation to update or supplement any forward-looking statements to reflect subsequent knowledge, events, or circumstances. We will also discuss adjusted EBITDA, a non-GAAP financial measure. This measure should not be considered a substitute for GAAP results. A reconciliation to net income is included in our earnings release. The third quarter 2026 earnings release is available in the Investors section of our website along with additional details on our financial results and our latest SEC filings. We encourage you to review those materials. A recording of today’s call will also be available on our website.
Now I’ll turn the call over to Gerard Michel. Gerard, please proceed.
Gerard Michel (Chief Executive Officer)
Thank you, David, and good morning. Delcath’s record third quarter of $35.1 million in revenue, up 71% from the third quarter in 2025, reflects the growing adoption of HEPZATO KIT and the hard work of both the Delcath and physician treatment teams. Just as importantly, we are delivering positive operating cash flow, which gives us the flexibility to support investment in both the treatment network and ongoing research that will expand the platform.
The growth and profitability was driven by strong new patient starts for the quarter. At approximately 0.6 new patient starts per site per month, we now have 33 active treatment centers in the U.S. Since our last update, we have added the University of Nebraska and AdventHealth. Two additional new centers have patients scheduled this month, and we expect at least one more activation before year end, which would bring us to at least 36 centers by year end.
The addition of AdventHealth is especially meaningful given its scale as one of the nation’s largest integrated health systems, with more than 50 hospitals, over 2,000 care sites, and roughly 4 million unique patients served each year, providing a robust platform for referral volume and system-wide utilization of HEPZATO. Our focus remains on both expanding the network and increasing utilization at existing centers. Through referral relationships, community physician education, and better coordination across the patient pathway, combination treatment with systemic therapy is increasingly becoming the norm. Most physicians view the two approaches as complementary rather than mutually exclusive. CHOPIN has provided an important foundation for this treatment strategy, and independent real-world experience continues to inform patient selection and sequencing strategy.
In the third quarter, the 1,000th commercial HEPZATO treatment in the United States took place, which reflects the broadening acceptance of the therapy across a growing number of centers. In addition, University Hospital Southampton delivered their 500th CHEMOSAT procedure, led by Dr. Sachan Modi. This illustrates how once the center gains experience and sees results, the therapy tends to become firmly incorporated as an important component of standard of care.
On the clinical development side, the Phase 2 colorectal trial continues to enroll at a pace that supports an interim analysis in the middle of next year. As we’ve discussed in prior calls, enrollment in the breast cancer trial has been slower than initially anticipated. We are not yet in a position to provide guidance on the timing of an interim analysis. However, the first patient was dosed in July at the European Institute of Oncology in Milan, and we now have multiple sites recruiting patients in Europe and the U.S., and we continue to work with sites to support enrollment.
We are also expanding our pipeline with a planned IND submission for cholangiocarcinoma in early 2027 and, pending FDA agreement, completion of ongoing preclinical development of an oxaliplatin-based PHP program by mid-2027 to support a subsequent study. Both clinical programs have substantial strategic significance. The cholangiocarcinoma trial has broad support in the medical community based on both clinical development experience with CHEMOSAT in Europe and the very high unmet need.
Delcath is exploring the oxaliplatin-based PHP products because physicians are already highly familiar and comfortable with oxaliplatin as a standard backbone agent in colorectal and other GI cancer treatments. By delivering high-dose oxaliplatin regionally through the hepatic delivery system and reducing systemic exposure, we may be able to incorporate it in a standard FOLFOX regimen in patients with liver-dominant cancers without meaningfully increasing toxicity, particularly cumulative neuropathy.
From a biology standpoint, many oncologists view oxaliplatin as a better match to colorectal liver metastases and therefore may be more comfortable using oxaliplatin-based PHP treatment in a first- or second-line setting versus a melphalan-based product. We will provide updates on these two programs as they reach regulatory and operational milestones in 2027. With that, I’ll turn the call over to Sandra.
Sandra Pennell (SVP Finance)
Thank you, Gerard. For the third quarter of 2026, total revenue was $35.1 million compared with $20.6 million in the third quarter of 2025. HEPZATO KIT revenue was $32.7 million compared to $19.3 million in the prior-year third quarter. This represents a HEPZATO volume increase of 19% from the prior quarter and 72% year over year. CHEMOSAT revenue was $2.4 million compared with $1.3 million in the prior-year third quarter. Gross margin was 89% for the quarter compared with 87% in the third quarter of 2025. Research and development expense was $11 million compared with $8 million in the prior-year quarter. The increase primarily reflects additional clinical headcount and increased clinical trial activity. Selling, general, and administrative expense was $13.1 million compared with $10.3 million in the prior-year quarter. This increase reflects our continued investment in commercial expansion.
Net income was $7 million compared with $0.8 million in the third quarter of 2025. On a non-GAAP basis, adjusted EBITDA was $11.5 million compared with $5.3 million in the prior-year quarter. These results demonstrate the operating leverage in our commercial model. At the same time, quarterly profitability may vary as we continue to invest in treatment network expansion and clinical development. We ended the quarter with $104.3 million in cash and investments and no debt. Cash generated from operations was $8.2 million for the quarter compared with $4.8 million in the prior-year quarter.
Turning to our 2026 outlook, we are raising our full-year total revenue guidance to a range of $115 million to $117 million. We expect at least a 41% HEPZATO KIT volume growth over 2025. Our guidance reflects $25.8 million to $27.8 million total revenue in the fourth quarter of 2026, a year-on-year growth of approximately 25% to 34%. We also expect full-year gross margin of 87% to 89% and positive adjusted EBITDA. Thank you for joining us today. I’ll now turn the call back to the operator to open the lines for questions. Operator, we are opening the line for questions.
OPERATOR
Thank you, ladies and gentlemen. We will now conduct a question-and-answer session. If you would like to ask a question, please press star-one on your telephone keypad. A confirmation tone will indicate your line is in the queue. You may press star-two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment please while we poll for questions.
The first question comes from Marie Sibold with U.S. Bank. Please go ahead.
Marie Sibold (Analyst at U.S. Bank)
Hi, good morning, Gerard and Sandra, and congrats on a really impressive quarter. I wanted to ask a little bit about what you think drove the outperformance this quarter. Certainly several million more than I think folks were expecting. And it looks like your outlook is calling for a return to sort of a more normalized level in Q4. I’m not sure if that’s some conservatism, but maybe you could get into a little more detail about what you saw at centers in the quarter and what your expectations are going forward from here.
Gerard Michel (Chief Executive Officer)
Yeah, I think probably two primary drivers for—well, three, I think—for the strong results. One is I think CHOPIN and combination therapy or sequencing therapy is becoming increasingly the norm, so we’re no longer getting behind systemic treatments. I don’t believe we have a lot of first-line usage, but when the patients make it to our centers, if they’re already on IPI/NIVO, for an example, or tebi, they’ll add this on pretty quickly. Or if they’re treatment naïve, they’ll start with sequencing.
Not all centers are doing that, but I would say it’s probably more the norm now than the exception for background systemic therapy with PHP. So that essentially kind of moves us up a bit. And I think the patients stay on therapy longer on combination therapy, so that should help the number of doses they get as well. I think the second thing is just docs are seeing results and the word is getting out there to the patient community, and the patients are increasingly asking for the therapy. So that helps quite a bit as well when they show up fairly well informed about it. And then lastly, I think this time last year we were faced with significant headwinds from clinical trials. There’s less of that going on now. I would add a fourth point, and that is that our teams did do a good job.
We incentivized the sales force to try to get backup teams in place. It definitely was a component of scheduling last year, and quite a few centers we managed to get backups both for the perfusionists, the anesthesiologists, as well as the IRs, which by definition increases the capacity at these centers. So there’s four reasons for you, Marie.
Marie Sibold (Analyst at U.S. Bank)
Very good. Okay, well, that’s helpful. I’m glad to hear all of that is working together and driving results. And then maybe a question for Sandra because I’d like to hear about pipeline, but I’m sure some of my colleagues on the line will also ask. I guess on the spending side, saw that the R&D headcount went up as you do more in the pipeline programs. So is it fair to assume that R&D spending is kind of at this new level, that we should kind of sustain that level, and then SG&A sort of fluxes with revenue, or how would you sort of characterize spending going forward?
Thank you for taking the question.
Sandra Pennell (SVP Finance)
Yeah, I think that’s correct. As we mentioned, I think at the first couple of calls this year that spending was a little bit slower on the R&D side due to slower than anticipated ramp in the trials. But now in Q3, we’ve seen that come back a bit. So this is probably more of the norm to increase quarter over quarter as we go into 2027. And then from an SG&A perspective, yes, I think we have a fully staffed, almost fully staffed commercial team based on the expansion to the nine regions.
So this is likely a little bit more flat of a growth going into the fourth quarter and then next year, but also will flex a bit with the increase in sales quarter over quarter.
Marie Sibold (Analyst at U.S. Bank)
All right, thank you so much.
OPERATOR
Thank you. The next question comes from John Newman with Canaccord. Please go ahead.
John Newman (Analyst at Canaccord Genuity)
Hi. Thanks for taking my question. Another really great quarter—congrats on that. Just had a question about the progress in colorectal cancer. Gerard, I thought I heard you say we could get an update in the middle of next year, but I just wanted to double check that. I believe you may have previously mentioned year-end ’27. And then just curious if you can give us any color on enrollment there. Thank you.
Gerard Michel (Chief Executive Officer)
I’ve noticed you guys do a good job paying attention to what I said last year, last call, and what changes. Yeah, you’re right. I was more towards the back end of next year, and now I did say closer to mid this year. So, I don’t know, Q2, Q3 is probably when we’ll provide an update on the interim results.
John Newman (Analyst at Canaccord Genuity)
Okay, thank you.
OPERATOR
Thank you. The next question comes from Chase Knickerbocker with Craig-Hallum. Please go ahead.
Chase Knickerbocker (Analyst at Craig-Hallum Capital Group)
Good morning. I’ll add my congrats on a great quarter as well. Maybe just double click on guidance. You know, Q4 is an implied step down in your guide that seemingly wouldn’t be commensurate with that 0.6 new patient starts per site per month you mentioned. So I guess, what’s your level of visibility to that? And then can you just walk us through your assumptions to get to that implied Q4? Thanks.
Gerard Michel (Chief Executive Officer)
Yeah, I think that the primary reason you’re seeing that step down is, you know, we’re assuming, and we did see this last Q4, we essentially lose two weeks, close to two weeks, due to the holidays. So, you know, if you take that out, that accounts for the majority of what you’re characterizing as a step down. Could we be wrong? I’d love to be wrong, but I think it’s prudent to assume that in terms of scheduling, we look at when patients were scheduled last year, look at the calendar this year, we took out the days where we don’t think we’ll see any treatment.
So that’s the primary driver for, again, what you characterize as a step down.
Chase Knickerbocker (Analyst at Craig-Hallum Capital Group)
So fair on kind of the rest of the quarter to kind of expecting new patient starts that are fairly consistent with what we saw in Q3 and Q2. And then I just have a follow up.
Gerard Michel (Chief Executive Officer)
Yeah, and we’ve seen it bounce all the way around. But no, we saw fewer—we generally see fewer—new patient starts in the fourth quarter. So we’re taking, you know, doing the best we can, but we’re taking into account what we’ve seen in prior fourth quarters in terms of new patient starts as well as what we’ve taken into account what we’ve seen in terms of weeks, days where patients are actually scheduled for treatment.
Chase Knickerbocker (Analyst at Craig-Hallum Capital Group)
Understood. And then just maybe with the final rules getting posted last week, any thoughts that you have around the 340B changes and any potential impact to your business as we think about ’27.
Gerard Michel (Chief Executive Officer)
Yeah, I think we’ve given a fair amount of thought, as you might expect. I think what we believe is this will be a net neutral to a net positive for us in terms of ASP without any impact on volume one way or the other.
Chase Knickerbocker (Analyst at Craig-Hallum Capital Group)
Got it. Thank you, Gerard.
OPERATOR
Thank you. The next question comes from Yale Jen. Please go ahead.
Yale Jen (Analyst)
Good morning and thanks for taking the questions and congrats on very good quarters. I just want to get a little bit deeper on the fourth quarter. We already have one month past in October. So what is, I mean, you get from your new guidance? I’m just curious whether—how is the October numbers sort of in line with your expectation for the fourth quarter?
Gerard Michel (Chief Executive Officer)
Well, I’ll just say that the fourth quarter—I mean, the October numbers clearly input into the guidance we gave. Other inputs are what we saw in past fourth quarters in terms of new patient starts as well as—I mean, last year the new patient starts were 0.3 to 0.35 in Q4. So, you know, if we assumed continued 0.6, I think we’d be being a bit aggressive. So I’m not going to speak to precisely what we’re seeing in October, but we’re very comfortable with our guidance.
Yale Jen (Analyst)
Okay, great. That’s very helpful. And again, congrats on the overall good quarters and moving forward.
Gerard Michel (Chief Executive Officer)
Thank you, Yale.
OPERATOR
Thank you once again. If you have a question, please press star-one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. The next question comes from Sayam Pakula Ramakanth with HC Wainwright. Please go ahead.
Sayam Pakula Ramakanth (Analyst at HC Wainwright)
Thank you. This is RK from HC Wainwright. Good morning, Gerard and Sandra. Congratulations on the quarter. And I guess now we got rid of the third quarter cobwebs from last year, so that’s good. Thinking through the 0.6 new starts per site per month that you stated for the third quarter, you know, where did that additional starts come from? Was that new patients or repeat treatments? And also, the growth that you’re seeing—are they broad based among, you know, some of your mature centers that have been with you for a while now?
Gerard Michel (Chief Executive Officer)
Yeah, so the 0.6 new patient starts by definition are new patients, but obviously returning patients, you know, round out the numbers. But I’ll let Kevin give some color on where we’re seeing this coming from.
Kevin Muir (Chief Commercial Officer)
Thank you, Gerard. As he mentioned earlier in the call, with the 0.6 new patients, that has been pretty broad based across our treatment centers. However, our larger centers have increased capacity and have increased the treatment team. So centers like MD Anderson and Mass General have really picked up the level of treatments that they do in enrolling new patients.
Sayam Pakula Ramakanth (Analyst at HC Wainwright)
Thanks for that. And then, Gerard, you also stated Advent, which is an integrated health network, as a key addition during this quarter. How much energy is being spent in trying to get such centers on board? Because as you stated, once you get some of these centers up, you can have broad-based patient adoption or adoption into the system.
Kevin Muir (Chief Commercial Officer)
Well, what’s exciting for us is when sites like AdventHealth come on that have over 50 hospitals, and within their integrated network they also have a host of primary care centers and general oncologists that are within that integrated network, and they help us funnel patients with metastatic uveal melanoma to these treatment centers. So Advent in and of itself is large, but it’s not unique. A lot of our other centers—some of those that I mentioned—have similar networks of oncologists that are now beginning to refer their patients into specific treatment centers that offer HEPZATO KIT.
Sayam Pakula Ramakanth (Analyst at HC Wainwright)
Thanks for that. One last question. I think you said 36 centers is what you’re looking at for the end of the year. What’s the push and pull on that number? Would—could we be seeing more than that number?
Gerard Michel (Chief Executive Officer)
Thanks. Yeah, we mentioned we have two additional sites with patients scheduled right now in the next week—I think, yes, couple weeks—and, you know, the danger there is they get canceled, and that happens occasionally. And we probably have three others where we think it’s possible they could get a patient in by December. And I think, as everybody knows, I’ve been woefully inaccurate in my projections for new centers, but I’ve also overperformed on the new starts per center.
So we’ve done okay. But, you know, we’ve got a good—kind of the two that are scheduled, there’s probably six or so that could go now. Out of that, two go, three go, four go—I don’t know, we’ll see. But I, you know, want to give color because I know there’s, you know, an appetite to know what’s going on out there in terms of center starts. So I’m, you know, letting you know everything we have. And I think given the variability we’ve seen in the past, hopefully you guys understand that there’s, you know, no guarantees on those numbers, but we are definitely headed in the right direction.
Sayam Pakula Ramakanth (Analyst at HC Wainwright)
Thank you. Thanks for taking all my questions, Gerard.
OPERATOR
Thank you. There are no questions at this time. This now concludes the conference call for today. Thank you for your participation. You may now disconnect your lines.
Disclaimer: This transcript is provided for informational purposes only. While we strive for accuracy, there may be errors or omissions in this automated transcription. For official company statements and financial information, please refer to the company’s SEC filings and official press releases. Corporate participants’ and analysts’ statements reflect their views as of the date of this call and are subject to change without notice.
Recent Comments